argenex (ARGX) Competitors $711.62 +0.53 (+0.07%) Closing price 09/26/2025 04:00 PM EasternExtended Trading$712.32 +0.70 (+0.10%) As of 09/26/2025 04:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ARGX vs. SNY, GSK, TAK, ONC, INSM, BNTX, TEVA, GMAB, SMMT, and RDYShould you be buying argenex stock or one of its competitors? The main competitors of argenex include Sanofi (SNY), GSK (GSK), Takeda Pharmaceutical (TAK), BeOne Medicines (ONC), Insmed (INSM), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Summit Therapeutics (SMMT), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical products" industry. argenex vs. Its Competitors Sanofi GSK Takeda Pharmaceutical BeOne Medicines Insmed BioNTech Teva Pharmaceutical Industries Genmab A/S Summit Therapeutics Dr. Reddy's Laboratories argenex (NASDAQ:ARGX) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership and media sentiment. Which has stronger earnings & valuation, ARGX or SNY? Sanofi has higher revenue and earnings than argenex. Sanofi is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratioargenex$3.05B14.27$833.04M$19.5036.49Sanofi$45.74B2.44$6.02B$4.1610.95 Does the media prefer ARGX or SNY? In the previous week, Sanofi had 14 more articles in the media than argenex. MarketBeat recorded 20 mentions for Sanofi and 6 mentions for argenex. argenex's average media sentiment score of 1.07 beat Sanofi's score of 0.55 indicating that argenex is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment argenex 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sanofi 8 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Positive Is ARGX or SNY more profitable? argenex has a net margin of 40.98% compared to Sanofi's net margin of 21.47%. argenex's return on equity of 21.06% beat Sanofi's return on equity.Company Net Margins Return on Equity Return on Assets argenex40.98% 21.06% 18.25% Sanofi 21.47%16.86%9.63% Do analysts rate ARGX or SNY? argenex presently has a consensus price target of $789.20, indicating a potential upside of 10.90%. Sanofi has a consensus price target of $62.67, indicating a potential upside of 37.61%. Given Sanofi's stronger consensus rating and higher possible upside, analysts clearly believe Sanofi is more favorable than argenex.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score argenex 0 Sell rating(s) 1 Hold rating(s) 20 Buy rating(s) 3 Strong Buy rating(s) 3.08Sanofi 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.11 Do insiders and institutionals have more ownership in ARGX or SNY? 60.3% of argenex shares are owned by institutional investors. Comparatively, 14.0% of Sanofi shares are owned by institutional investors. 2.4% of argenex shares are owned by insiders. Comparatively, 1.0% of Sanofi shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more risk & volatility, ARGX or SNY? argenex has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500. Comparatively, Sanofi has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500. Summaryargenex beats Sanofi on 11 of the 17 factors compared between the two stocks. Get argenex News Delivered to You Automatically Sign up to receive the latest news and ratings for ARGX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARGX vs. The Competition Export to ExcelMetricargenexMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$43.55B$3.12B$5.72B$10.36BDividend YieldN/A2.43%5.79%4.70%P/E Ratio36.4921.1976.3726.25Price / Sales14.27417.31537.40176.34Price / Cash239.5644.9237.3261.02Price / Book7.869.7412.416.36Net Income$833.04M-$53.02M$3.31B$272.06M7 Day Performance-3.41%3.79%1.29%0.34%1 Month Performance1.07%7.84%3.71%5.77%1 Year Performance32.74%18.28%62.66%27.44% argenex Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARGXargenex4.1537 of 5 stars$711.62+0.1%$789.20+10.9%+32.7%$43.55B$3.05B36.491,599Positive NewsSNYSanofi4.1326 of 5 stars$47.01-1.3%$62.67+33.3%-21.0%$115.43B$45.74B11.3082,878GSKGSK1.78 of 5 stars$40.91+0.6%$37.38-8.6%-2.2%$83.32B$31.63B18.9468,629Dividend CutTAKTakeda Pharmaceutical2.351 of 5 stars$15.04-0.2%N/A+1.4%$47.84B$4.48T50.1247,455ONCBeOne Medicines1.7485 of 5 stars$337.82+1.0%$336.30-0.4%N/A$37.03B$4.56B-195.2711,000INSMInsmed3.08 of 5 stars$145.03+0.2%$139.86-3.6%+89.1%$30.66B$363.71M-25.401,271BNTXBioNTech2.6703 of 5 stars$98.72+2.6%$134.56+36.3%-17.0%$23.73B$2.88B-61.706,772TEVATeva Pharmaceutical Industries2.6099 of 5 stars$18.87+2.8%$24.71+31.0%+4.8%$21.64B$16.54B-117.9436,830Analyst ForecastGMABGenmab A/S3.6649 of 5 stars$28.60+1.1%$39.25+37.2%+19.5%$18.35B$3.26B14.372,682News CoverageAnalyst UpgradeSMMTSummit Therapeutics2.9341 of 5 stars$19.10+1.1%$31.87+66.8%+0.3%$14.19B$700K-18.91110Analyst ForecastRDYDr. Reddy's Laboratories2.9256 of 5 stars$14.59-1.9%$16.95+16.2%-10.9%$12.18B$3.81B22.1127,811Positive News Related Companies and Tools Related Companies SNY Alternatives GSK Alternatives TAK Alternatives ONC Alternatives INSM Alternatives BNTX Alternatives TEVA Alternatives GMAB Alternatives SMMT Alternatives RDY Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARGX) was last updated on 9/28/2025 by MarketBeat.com Staff From Our PartnersTrump Devises the Death of the IRS ☠️Trump has just signed an executive order creating America's first-ever National Investment Fund — a game-chang...Angel Publishing | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredSean Hannity: Help Protect Your RetirementThis Guide to retirement protection has helped thousands protect over $3 billion dollars in retirement savings...Goldco Precious Metals | SponsoredThis is the “End of Tesla” as we know it…Jeff has identified five of the past seven number-one performing tech stocks — before they took off. His Tesla...Brownstone Research | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding argenex SE Please log in to your account or sign up in order to add this asset to your watchlist. Share argenex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
